Project Grant R41CA302048
Award Date 9/2/26
Completion Date 8/31/27
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
- The National Cancer Institute awarded the University of Kansas Medical Center Research Institute, Inc. $398,544 on April 8, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct pre-clinical evaluation of a highly selective SMARCA2 degrader in therapy-resistant triple-negative breast cancer. The research addresses mechanisms of resistance to neoadjuvant systemic therapy in triple-negative breast cancer patients with residual disease. The project leverages the recipient's...
- The National Cancer Institute awarded $400,000 to Dauntless Biotherapeutics, Inc. on August 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop CD155-targeted antibody-drug conjugates for metastatic and triple-negative breast cancer. The project advances therapeutic candidates that combine direct tumor cytotoxicity with restoration of anti-tumor immunity. CD155 is expressed in over 60% of breast cancers, including triple-negative, HER2-positive, and HER2-low...
- The National Cancer Institute awarded the University of Tennessee Health Science Center $389,215 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop selective N-glycan biosynthesis inhibitors targeting metastatic triple-negative breast cancer. The research employs structure-guided medicinal chemistry to optimize DPAGT1 (dolichyl-phosphate N-acetylglucosaminephosphotransferase 1) inhibitors, the first committed enzyme in N-glycan biosynthesis. The project...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Natsar Pharmaceuticals, Inc. a $1.63 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) on September 22, 2025, for the development of RK-33, a small molecule inhibitor targeting DDX3 (DEAD-box helicase 3) as a therapeutic candidate for triple-negative breast cancer (TNBC). The grant supports drug development activities through August 31, 2027, advancing a rationally designed compound that has...
- The National Cancer Institute awarded Vanderbilt University Medical Center $400,313 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate the AR antagonist darolutamide combined with standard-of-care therapy in triple-negative breast cancer patients, specifically those with the luminal androgen receptor subtype characterized by greater than 80 percent AR positivity by immunohistochemistry. The project addresses a significant clinical gap: the LAR subtype,...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- The National Cancer Institute awarded Emory University $602,847 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the N-glycan modification pathway as a therapeutic target for triple-negative breast cancer, particularly in BRCA1-deficient patients. The project examines the role of MAN1C1, a glycosyl hydrolase, in breast cancer progression, immune evasion, and therapeutic resistance. The research addresses a critical gap: approximately 50–70 percent of...
- The National Cancer Institute awarded $668,878 to the University of Texas at Austin on April 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates targeting CD44 variant 9 for advanced and treatment-resistant breast cancer. The research addresses the clinical need for new therapeutic options for patients with triple-negative and heavily treated hormone receptor-positive metastatic breast cancer who have relapsed or progressed after current...
- The National Institutes of Health National Cancer Institute awarded Vanderbilt University Medical Center $695,884 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate selective loss of HLA gene products in triple-negative breast cancer immunobiology. The research examines how tumor cells evade immune checkpoint inhibition through downregulation or deletion of MHC-I (major histocompatibility complex I) expression. Preliminary data from the recipient's...
- The National Cancer Institute awarded Seak Therapeutics, LLC $399,981 on September 19, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop SEAK193, a potent antimitotic agent designed to treat breast cancer brain metastasis. The work encompasses Phase 1 de-risking of SEAK193 as a single agent to assess its viability as a clinical candidate for treating breast cancer brain metastases, as well as brain metastases from lung cancer and melanoma and primary brain tumors...